Author’s response to reviews

Title: The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis

Authors:

Christopher Rowe (christopher.rowe@hnehealth.nsw.gov.au)
Sam Faulkner (sam.faulkner@newcastle.edu.au)
Jonathan Paul (jonathan.paul@newcastle.edu.au)
Jorge Tolosa (jorge.tolosa@newcastle.edu.au)
Craig Gedye (craig.gedye@newcastle.edu.au)
Cino Bendinelli (cino.bendinelli@hnehealth.nsw.gov.au)
Katie Wynne (Katie-jane.wynne@hnehealth.nsw.gov.au)
Shaun McGrath (mcgrath@newcastleendocrinology.com)
John Attia (john.attia@newcastle.edu.au)
Roger Smith (roger.smith@newcastle.edu.au)
Hubert Hondermarck (hubert.hondermarck@newcastle.edu.au)

Version: 3 Date: 17 Oct 2019

Author’s response to reviews:

Dr Ciaràn Martin Fitzpatrick
Editor in Chief
BMC Endocrine Disorders

Dear Ciaràn,

Re: BEND-D-19-00228R2 The precursor for nerve growth factor (proNGF) is not a serum or biopsy-rinse biomarker for thyroid cancer diagnosis.

Thank you for your considered review of our research.

We are thankful for the comments of Reviewer 2 confirming that all their comments have now been fully addressed.
We have carefully reviewed the two points raised by Reviewer 3:

1. Page 9, Line 199-201. We agree there was a typographical error, where a single parenthesis was left in the text inadvertently. This parenthesis has been removed and the sentence now makes grammatical sense.

2. Supplementary Table 2: We have removed the definition of the abbreviation for ‘FTC’, as this abbreviation was not included in the table, as was correctly identified by Reviewer 3.

Aside from addressing these two typographical errors, no other changes were requested by the reviewers, and no other changes have been introduced to the manuscript in this revision.

We are confident that we have fully addressed all of the issues raised by the three reviewers.

We thank you for your consideration.

Dr Christopher Rowe
On behalf of the authors